Download PDF
Semin Neurol 2013; 33(03): 286-296
DOI: 10.1055/s-0033-1354594
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pharmacotherapy of Vestibular Disorders and Nystagmus

Michael Strupp
1   Department of Neurology, German Center for Vertigo and Balance Disorders
,
Olympia Kremmyda
1   Department of Neurology, German Center for Vertigo and Balance Disorders
,
Thomas Brandt
1   Department of Neurology, German Center for Vertigo and Balance Disorders
2   Institute for Clinical Neurosciences, University Hospital Munich, Campus Grosshadern, Munich, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
21 September 2013 (online)

    Permissions and Reprints

Abstract

Vertigo and dizziness are with a life-time prevalence of ∼30% among the most common symptoms and are often associated with nystagmus or other oculomotor disorders. The prerequisite for a successful treatment is a precise diagnosis of the underlying disorder. In this overview, the current pharmacological treatment options for peripheral and central vestibular, cerebellar, and oculomotor disorders including nystagmus are described. There are basically seven groups of drugs that can be used (the “7 As”): antiemetics; anti-inflammatory, anti-Menière's, and antimigraine medications; antidepressants, anticonvulsants, and aminopyridines. In acute vestibular neuritis, recovery of the peripheral vestibular function can be improved by treatment with oral corticosteroids. In Menière's disease, a long-term high-dose treatment with betahistine-dihydrochloride (at least 48 mg three times daily) had a significant effect on the frequency of the attacks; the underlying mode of action is evidently an increase in inner-ear blood flow. The use of aminopyridines is a well-established therapeutic principle in the treatment of downbeat and upbeat nystagmus as well as episodic ataxia type 2 and cerebellar gait disorders. As was shown in animal experiments, these potassium channel blockers increase the activity and excitability and normalize irregular firing of cerebellar Purkinje cells. They evidently augment the inhibitory influence of these cells on vestibular and deep cerebellar nuclei. A few studies showed that baclofen improves periodic alternating nystagmus; gabapentin and memantine improve pendular and infantile nystagmus. However, many other eye-movement disorders such as ocular flutter, opsoclonus, central positioning, and see-saw nystagmus are still difficult to treat. Although substantial progress has been made, further state-of-the-art trials must still be performed on many vestibular and oculomotor disorders, namely Menière's disease, vestibular paroxysmia, vestibular migraine, and many forms of central eye-movement disorders.

Keywords

vestibular neuritis - Menière's disease - vestibular paroxysmia - vestibular migraine - episodic ataxia type 2 - downbeat nystagmus - upbeat nystagmus
 

  • References

  • 1 Neuhauser HK. Epidemiology of vertigo. Curr Opin Neurol 2007; 20 (1) 40-46
    CrossrefPubMedGoogle Scholar
  • 2 Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 2011; 258 (7) 1207-1222
    CrossrefPubMedGoogle Scholar
  • 3 Huppert D, Strupp M, Mückter H, Brandt T. Which medication do I need to manage dizzy patients?. Acta Otolaryngol 2011; 131 (3) 228-241
    CrossrefPubMedGoogle Scholar
  • 4 Brandt T, Dieterich M, Strupp M. Vertigo and dizziness—common complaints. 2nd ed. London, England: Springer; 2013
    CrossrefGoogle Scholar
  • 5 Sekitani T, Imate Y, Noguchi T, Inokuma T. Vestibular neuronitis: epidemiological survey by questionnaire in Japan. Acta Otolaryngol (Stockh). 1993; 503 (Suppl): 9-12
    PubMedGoogle Scholar
  • 6 Schulz P, Arbusow V, Strupp M, Dieterich M, Rauch E, Brandt T. Highly variable distribution of HSV-1-specific DNA in human geniculate, vestibular and spiral ganglia. Neurosci Lett 1998; 252 (2) 139-142
    CrossrefPubMedGoogle Scholar
  • 7 Arbusow V, Schulz P, Strupp M , et al. Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol 1999; 46 (3) 416-419
    CrossrefPubMedGoogle Scholar
  • 8 Arbusow V, Theil D, Strupp M, Mascolo A, Brandt T. HSV-1 not only in human vestibular ganglia but also in the vestibular labyrinth. Audiol Neurootol 2001; 6 (5) 259-262
    CrossrefPubMedGoogle Scholar
  • 9 Theil D, Arbusow V, Derfuss T , et al. Prevalence of HSV-1 LAT in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes. Brain Pathol 2001; 11 (4) 408-413
    CrossrefPubMedGoogle Scholar
  • 10 Theil D, Derfuss T, Strupp M, Gilden DH, Arbusow V, Brandt T. Cranial nerve palsies: herpes simplex virus type 1 and varizella-zoster virus latency. Ann Neurol 2002; 51 (2) 273-274
    CrossrefPubMedGoogle Scholar
  • 11 Theil D, Derfuss T, Paripovic I , et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003; 163 (6) 2179-2184
    CrossrefPubMedGoogle Scholar
  • 12 Dutia MB. Mechanisms of vestibular compensation: recent advances. Curr Opin Otolaryngol Head Neck Surg 2010; 18 (5) 420-424
    CrossrefPubMedGoogle Scholar
  • 13 Strupp M, Zingler VC, Arbusow V , et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004; 351 (4) 354-361
    CrossrefPubMedGoogle Scholar
  • 14 Goudakos JK, Markou KD, Franco-Vidal V, Vital V, Tsaligopoulos M, Darrouzet V. Corticosteroids in the treatment of vestibular neuritis: a systematic review and meta-analysis. Otol Neurotol 2010; 31 (2) 183-189
    CrossrefPubMedGoogle Scholar
  • 15 Karlberg ML, Magnusson M. Treatment of acute vestibular neuronitis with glucocorticoids. Otol Neurotol 2011; 32 (7) 1140-1143
    CrossrefPubMedGoogle Scholar
  • 16 Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 2011; (5) CD008607
    PubMedGoogle Scholar
  • 17 Wegner I, van Benthem PP, Aarts MC, Bruintjes TD, Grolman W, van der Heijden GJ. Insufficient evidence for the effect of corticosteroid treatment on recovery of vestibular neuritis. Otolaryngol Head Neck Surg 2012; 147 (5) 826-831
    CrossrefPubMedGoogle Scholar
  • 18 Gürkov R, Flatz W, Louza J, Strupp M, Ertl-Wagner B, Krause E. In vivo visualized endolymphatic hydrops and inner ear functions in patients with electrocochleographically confirmed Ménière's disease. Otol Neurotol 2012; 33 (6) 1040-1045
    PubMedGoogle Scholar
  • 19 Yeh TH, Herman P, Tsai MC, Tran Ba Huy P, Van den Abbeele T. A cationic nonselective stretch-activated channel in the Reissner's membrane of the guinea pig cochlea. Am J Physiol 1998; 274 (3 Pt 1) C566-C576
    PubMedGoogle Scholar
  • 20 Carey JP, Hirvonen T, Peng GC , et al. Changes in the angular vestibulo-ocular reflex after a single dose of intratympanic gentamicin for Ménière's disease. Ann N Y Acad Sci 2002; 956: 581-584
    CrossrefPubMedGoogle Scholar
  • 21 Magnusson M, Padoan S. Delayed onset of ototoxic effects of gentamicin in treatment of Meniere's disease. Rationale for extremely low dose therapy. Acta Otolaryngol (Stockh) 1991; 111: 671-676
    CrossrefPubMedGoogle Scholar
  • 22 Postema RJ, Kingma CM, Wit HP, Albers FW, Van Der Laan BF. Intratympanic gentamicin therapy for control of vertigo in unilateral Meniere's disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol 2008; 128 (8) 876-880
    CrossrefPubMedGoogle Scholar
  • 23 Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Ménière's disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol 2004; 124 (2) 172-175
    CrossrefPubMedGoogle Scholar
  • 24 Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. Cochrane Database Syst Rev 2011; (3) CD008234
    PubMedGoogle Scholar
  • 25 Colletti V, Carner M, Colletti L. Auditory results after vestibular nerve section and intratympanic gentamicin for Ménière's disease. Otol Neurotol 2007; 28 (2) 145-151
    CrossrefPubMedGoogle Scholar
  • 26 Huppert D, Strupp M, Brandt T. Long-term course of Ménière's disease revisited. Acta Otolaryngol 2010; 130 (6) 644-651
    CrossrefPubMedGoogle Scholar
  • 27 Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005; 133 (2) 285-294
    CrossrefPubMedGoogle Scholar
  • 28 Phillips JS, Westerberg B. Intratympanic steroids for Ménière's disease or syndrome. Cochrane Database Syst Rev 2011; (7) CD008514
    PubMedGoogle Scholar
  • 29 Casani AP, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg 2012; 146 (3) 430-437
    CrossrefPubMedGoogle Scholar
  • 30 Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS ONE 2012; 7 (6) e39086
    CrossrefPubMedGoogle Scholar
  • 31 Strupp M, Cnyrim C, Brandt T. Vertigo and dizziness: Treatment of benign paroxysmal positioning vertigo, vestibular neuritis and Ménière's disease. In: Candelise L, , ed. Evidence-based Neurology—Management of Neurological Disorders. Oxford, England: Blackwell Publishing; 2007: 59-69
    CrossrefGoogle Scholar
  • 32 Strupp M, Hupert D, Frenzel C , et al. Long-term prophylactic treatment of attacks of vertigo in Ménière's disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol 2008; 128 (5) 520-524
    CrossrefPubMedGoogle Scholar
  • 33 Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Ménière's disease: a case series. Eur Arch Otorhinolaryngol 2011; 268 (8) 1237-1240
    CrossrefPubMedGoogle Scholar
  • 34 Brandt T, Dieterich M. Vestibular paroxysmia: vascular compression of the eighth nerve?. Lancet 1994; 343 (8900) 798-799
    PubMedGoogle Scholar
  • 35 Strupp M, von Stuckrad-Barre S, Brandt T, Tonn JC. Teaching neuroimages: compression of the eighth cranial nerve causes vestibular paroxysmia. Neurology 2013; 80 (7) e77
    CrossrefPubMedGoogle Scholar
  • 36 Hüfner K, Barresi D, Glaser M , et al. Vestibular paroxysmia: diagnostic features and medical treatment. Neurology 2008; 71 (13) 1006-1014
    CrossrefPubMedGoogle Scholar
  • 37 Lempert T, Olesen J, Furman J , et al. Vestibular migraine: diagnostic criteria. J Vestib Res 2012; 22 (4) 167-172
    CrossrefPubMedGoogle Scholar
  • 38 Reploeg MD, Goebel JA. Migraine-associated dizziness: patient characteristics and management options. Otol Neurotol 2002; 23 (3) 364-371
    CrossrefPubMedGoogle Scholar
  • 39 Neuhauser H, Radtke A, von Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003; 60 (5) 882-883
    CrossrefPubMedGoogle Scholar
  • 40 Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Grand Duche Luxemb 2004; (2) 103-108
    PubMedGoogle Scholar
  • 41 Baier B, Winkenwerder E, Dieterich M. “Vestibular migraine”: effects of prophylactic therapy with various drugs. A retrospective study. J Neurol 2009; 256 (3) 436-442
    CrossrefPubMedGoogle Scholar
  • 42 Ophoff RA, Terwindt GM, Vergouwe MN , et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87 (3) 543-552
    CrossrefPubMedGoogle Scholar
  • 43 Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62 (1) 17-22
    CrossrefPubMedGoogle Scholar
  • 44 Griggs RC, Moxley III RT, Lafrance RA, McQuillen J. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 1978; 28 (12) 1259-1264
    CrossrefPubMedGoogle Scholar
  • 45 Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62 (9) 1623-1625
    CrossrefPubMedGoogle Scholar
  • 46 Strupp M, Kalla R, Claassen J , et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77 (3) 269-275
    CrossrefPubMedGoogle Scholar
  • 47 Alviña K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 2010; 30 (21) 7258-7268
    CrossrefPubMedGoogle Scholar
  • 48 Weisz CJ, Raike RS, Soria-Jasso LE, Hess EJ. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. J Neurosci 2005; 25 (16) 4141-4145
    CrossrefPubMedGoogle Scholar
  • 49 Claassen J, Teufel J, Kalla R, Spiegel R, Strupp M. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J Neurol 2013; 260 (2) 668-669
    CrossrefPubMedGoogle Scholar
  • 50 Stayte M, Reeves B, Wortham C. Ocular and vision defects in preschool children. Br J Ophthalmol 1993; 77 (4) 228-232
    CrossrefPubMedGoogle Scholar
  • 51 Wagner JN, Glaser M, Brandt T, Strupp M. Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry 2008; 79 (6) 672-677
    CrossrefPubMedGoogle Scholar
  • 52 Leigh RJ, Zee D. The neurology of eye movements. 4th ed. Oxford, New York: Oxford University Press; 2006
    Google Scholar
  • 53 Hüfner K, Stephan T, Kalla R , et al. Structural and functional MRIs disclose cerebellar pathologies in idiopathic downbeat nystagmus. Neurology 2007; 69 (11) 1128-1135
    CrossrefPubMedGoogle Scholar
  • 54 Kalla R, Deutschlander A, Hufner K , et al. Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology 2006; 66 (2) 281-283
    CrossrefPubMedGoogle Scholar
  • 55 Strupp M, Schüler O, Krafczyk S , et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003; 61 (2) 165-170
    CrossrefPubMedGoogle Scholar
  • 56 Kalla R, Glasauer S, Büttner U, Brandt T, Strupp M. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 2007; 130 (Pt 9) 2441-2451
    CrossrefPubMedGoogle Scholar
  • 57 Tsunemi T, Ishikawa K, Tsukui K, Sumi T, Kitamura K, Mizusawa H. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia. J Neurol Sci 2010; 292 (1-2) 81-84
    CrossrefPubMedGoogle Scholar
  • 58 Kalla R, Spiegel R, Claassen J , et al. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus. J Neuroophthalmol 2011; 31 (4) 320-325
    CrossrefPubMedGoogle Scholar
  • 59 Claassen J, Spiegel R, Kalla R , et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 2013; ; Epub ahead of print
    PubMedGoogle Scholar
  • 60 Claassen J, Feil K, Bardins S , et al. Dalfampridine in patients with downbeat nystagmus-an observational study. J Neurol 2013; 260 (8) 1992-1996
    CrossrefPubMedGoogle Scholar
  • 61 Averbuch-Heller L, Tusa RJ, Fuhry L , et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997; 41 (6) 818-825
    CrossrefPubMedGoogle Scholar
  • 62 Kremmyda O, Zwergal A, la Fougère C, Brandt T, Jahn K, Strupp M. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. J Neurol 2013; 260 (1) 321-323
    CrossrefPubMedGoogle Scholar
  • 63 Schniepp R, Wuehr M, Neuhaeusser M , et al. 4-aminopyridine and cerebellar gait: a retrospective case series. J Neurol 2012; 259 (11) 2491-2493
    CrossrefPubMedGoogle Scholar
  • 64 Etzion Y, Grossman Y. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res 2001; 139 (4) 419-425
    CrossrefPubMedGoogle Scholar
  • 65 Glasauer S, Rössert C, Strupp M. The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus. Ann N Y Acad Sci 2011; 1233: 162-167
    CrossrefPubMedGoogle Scholar
  • 66 Hourez R, Servais L, Orduz D , et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 2011; 31 (33) 11795-11807
    CrossrefPubMedGoogle Scholar
  • 67 Bense S, Best C, Buchholz HG , et al. 18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus. Neuroreport 2006; 17 (6) 599-603
    CrossrefPubMedGoogle Scholar
  • 68 Glasauer S, Strupp M, Kalla R, Büttner U, Brandt T. Effect of 4-aminopyridine on upbeat and downbeat nystagmus elucidates the mechanism of downbeat nystagmus. Ann N Y Acad Sci 2005; 1039: 528-531
    CrossrefPubMedGoogle Scholar
  • 69 Deuschl G, Wilms H. Clinical spectrum and physiology of palatal tremor. Mov Disord 2002; 17 (Suppl. 02) S63-S66
    PubMedGoogle Scholar
  • 70 Shaikh AG, Hong S, Liao K , et al. Oculopalatal tremor explained by a model of inferior olivary hypertrophy and cerebellar plasticity. Brain 2010; 133 (Pt 3) 923-940
    CrossrefPubMedGoogle Scholar
  • 71 Herishanu Y, Louzoun Z. Trihexyphenidyl treatment of vertical pendular nystagmus. Neurology 1986; 36 (1) 82-84
    CrossrefPubMedGoogle Scholar
  • 72 Jabbari B, Rosenberg M, Scherokman B, Gunderson CH, McBurney JW, McClintock W. Effectiveness of trihexyphenidyl against pendular nystagmus and palatal myoclonus: evidence of cholinergic dysfunction. Mov Disord 1987; 2 (2) 93-98
    CrossrefPubMedGoogle Scholar
  • 73 Leigh RJ, Burnstine TH, Ruff RL, Kasmer RJ. Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology 1991; 41 (11) 1737-1741
    CrossrefPubMedGoogle Scholar
  • 74 Starck M, Albrecht H, Pöllmann W, Straube A, Dieterich M. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1997; 244 (1) 9-16
    PubMedGoogle Scholar
  • 75 Starck M, Albrecht H, Pollmann W, Dieterich M, Straube A. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 2010; 257 (3) 322-327
    CrossrefPubMedGoogle Scholar
  • 76 Tomsak RL, Remler BF, Averbuch-Heller L, Chandran M, Leigh RJ. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol 1995; 119 (4) 489-496
    PubMedGoogle Scholar
  • 77 Leigh RJ, Robinson DA, Zee DS. A hypothetical explanation for periodic alternating nystagmus: instability in the optokinetic-vestibular system. Ann N Y Acad Sci 1981; 374: 619-635
    CrossrefPubMedGoogle Scholar
  • 78 Stahl JS, Plant GT, Leigh RJ. Medical treatment of nystagmus and its visual consequences. J R Soc Med 2002; 95 (5) 235-237
    CrossrefPubMedGoogle Scholar
  • 79 Self J, Lotery A. A review of the molecular genetics of congenital idiopathic nystagmus (CIN). Ophthalmic Genet 2007; 28 (4) 187-191
    CrossrefPubMedGoogle Scholar
  • 80 McLean R, Proudlock F, Thomas S, Degg C, Gottlob I. Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin. Ann Neurol 2007; 61 (2) 130-138
    CrossrefPubMedGoogle Scholar
  • 81 Feil K, Claassen J, Bardins S , et al. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot-trial. Neurology 2013; ; Epub ahead of print
    PubMedGoogle Scholar
  • 82 Strupp M, Teufel J, Habs M , et al. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J Neurol 2013; ; Epub ahead of print
    PubMedGoogle Scholar